Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 TREAT trispecific T cell engager, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 2301, a NK cell engager that is in preclinical trial for solid tumors; and GRC 65327, a Cbl-b inhibitor small molecule for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of hidradenitis suppurativa; and ISB 830-X8, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.